Sentence examples for genetics profiling from inspiring English sources

To date, five types of breast carcinomas have been recognized according to the molecular genetics profiling [ 2, 3].

In this study, we collaborated with Mike Tyers and combined zebrafish phenotypic chemical screens with yeast chemical genetics profiling to explore gene-environment interactions that modulate melanocyte pigmentation.

To allow rapid adaptation of the technique we optimized an application protocol of the CSMA cell patterning method for 85 cell types and applied the platform for functional genetics profiling of G-protein coupled receptor coding genes in cultured prostate cancer cells and non-malignant epithelial prostate cells, demonstrating the potential of the CSMAs for context specific target discovery.

"What worries me is a patient that would have that kind of a family history and go pay for a genetics profile that says that they're safe, so they decide not to go see their physician and not talk to somebody about it and put their head in the sand.

For over a decade preclinical progress in cancer biology, genetics, tumor profiling, and biotechnology have led to the successful development of a greatly expanded spectrum of biologically active agents that effectively target cancer-related proteins and pathways that improve individual antitumor effects with decreased toxicity for selective patients.

However, with the current revolution in genomics technologies, the question arises as to whether ecological phenomena such as plant invasion can be better understood by studies of genetics or gene expression profiling.

In the field of reverse genetics, gene expression profiling has been extensively utilized for functional inference of individual genes.

Our combined genome wide approaches show the power of yeast genetics and transcript profiling to define mode of functioning of bioactive substances.

Most studies have explored the utility of genetics and autoantibody profiling to predict response to anti-TNFα therapies in RA without satisfactory results for potential clinical use [ 16].

Another donor was Michael Andregg, then 31, co-founder of Halcyon Molecular, a high-profile genetics start-up in Silicon Valley: "I hope you preferably get better," he wrote to her, "but failing that get cryopreserved".

The first hypothesis was accepted: The differences in XARcomp serum activity between the study groups seem to reflect differences in chemical exposure profiles, genetics, and/or lifestyle factors.